Citigroup’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

Citigroup’s Portfolio FUSN Stock Details FUSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-25,268	Closed	-$539K	–	5843
2024 Q1	$539K	Buy	25,268 +23,958	+1,829%	+$287K	﹤0.01%	3516
2023 Q4	$12.6K	Buy	+1,310	New	+$6.37K	﹤0.01%	5138
2021 Q4	–	Sell	-2,414	Closed	-$19K	–	6143
2021 Q3	$19K	Sell	2,414 -160	-6%	-$1.35K	﹤0.01%	5261
2021 Q2	$21K	Buy	2,574 +1,777	+223%	+$15.3K	﹤0.01%	5284
2021 Q1	$9K	Sell	797 -457	-36%	-$5.34K	﹤0.01%	5722
2020 Q4	$15K	Buy	+1,254	New	+$15.8K	﹤0.01%	6808

Citigroup's FUSN Position: Q2 2024 in Review

Citigroup sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q2 2024, closing a stake of 25,268 shares — an estimated $539K sold.

Citigroup first reported a position in FUSN in Q4 2020 and held it in 6 quarters. The position peaked at $539K in Q1 2024. 0 funds tracked by Wall St. Rank hold FUSN as of Q2 2024.

Citigroup reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q2 2024 after selling out during the quarter.
Citigroup sold 25,268 Fusion Pharmaceuticals Inc. Common Shares shares in Q2 2024, an estimated $539K.
Citigroup first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q4 2020 and held it in 6 quarters.
Citigroup's Fusion Pharmaceuticals Inc. Common Shares position peaked at $539K in Q1 2024.
0 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q2 2024.

Based on Citigroup's 13F filing for Q2 2024, filed 12 Aug 2024.